Ax-003/Arimidex (Anastrozole) in the Adjuvant Therapy of Early Breast Cancer

Completed

• Conditions: Breast Cancer
• Interventions: Drug: Anastrozole

• Registration Number: NCT00638391
• Lead Sponsor: AstraZeneca

Brief Summary

The purpose of this study is the initial/followed by 5 year adjuvant therapy with Anastrozole.

Detailed Description

Not available

Study Timeline

• Study Start: 2005-05
• Study Completion: 2007-03
• Status Verified: 2008-03
• Study First Submitted: 2008-03-13
• Study First Submitted QC: 2008-03-18
• Study First Posted: 2008-03-19
• Last Update Submitted: 2008-03-19
• Last Update Posted: 2008-03-20

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 1600

Inclusion Criteria

• Postmenopausal women with early hormone receptor positive breast cancer/no metastasis

Exclusion Criteria

• None

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
1	Anastrozole	all patients treated with Anastrozole

Primary Outcome Measures

Name	Time	Method
evaluation of Anastrozole therapy as adjuvant treatment in post.menopausal women with not advanced breast cancer únder naturalistic conditions	12 months

Secondary Outcome Measures

Name	Time	Method
description of population treated with anastrozole	12 months
further information about the change of specific laboratory parameters	12 months